I like PING in the space> Ping Identity initiated with an Overweight at Wells Fargo 16:17 PING Wells Fargo analyst Andrew Nowinski initiated coverage of Ping Identity with an Overweight rating and $32 price target. The analyst believes Ping's PingOne Cloud Platform "will ultimately lead to long-term share gains." Further, the "powerful combination of several other key drivers" have the potential to lift the company's overall revenue growth to the 20% threshold or higher over time, Nowinski tells investors in a research note. He believes the stock's risk/reward is attractive.
It's Re-Buy Old favorites Day!!! Why has SAIL held $40 so well? SailPoint initiated with an Overweight at Wells Fargo 16:16 SAIL Wells Fargo analyst Andrew Nowinski initiated coverage of SailPoint with an Overweight rating and $54 price target. The company offers the most comprehensive IGA solution in the market, which should drive share gains in an increasingly complex market, the analyst tells investors in a research note. Nowinski adds that despite the company's solid outlook and growing mix of subscription revenue, SailPoint's valuation of enterprise value at 23-times expected 2023 revenue is a "modest discount" relative to peers.
OK Folks Here Is Your Playbook*********** BUYS-- BHVN- SNAP- DKNG- -watch- SAIL SFT PING REAL GET READY TO GUMMY CYTK **Biohaven Pharmaceutical sees Q3 NURTEC ODT net product revenue $136M 07:32 BHVN
Specifically, cryptocurrency miner Argo Blockchain (ARBK-1.8%) is highlighted in the note as the company's focus on energy efficiency is a potential competitive advantage, supporting lower cost mining operations. U.S. Energy(NASDAQ:USEG)+23.7%pre-market after agreeing to acquire oil and gas assets from Lubbock Energy Partners, Synergy Offshore and entities controlled by Sage Road Capital for $99.5M in cash and stock. U.S. Energy will issue more than 19.9M common shares, pay $1.25 M in cash and assume $3.3M of debt from the sellers. Upon the deal completion, the sellers will own 80.8% and existing U.S. Energy shareholders will own 19.2% of the company's outstanding common stock. The acquired assets from the Rockies, west Texas, Eagle Ford and Mid-Continent increase the company's estimated average daily production by 377% to 1,814 boe/day. Ryan Smith will continue as CEO of U.S. Energy, John Weinzierl, an owner of one of the sellers, will become the new chairman. At June 30, U.S. Energy had$6.6M in cash, no existing debt and 4.7M shares outstanding.
Ocugen enters supply, commercialization agreements for Covaxin and OCU410 07:57 OCGN IS THIS THE ONE YOU LIKE VAN-!
HUMMMMMMMMMMMMMMMMMMMMMMM Cathie Wood's ARK Investment bought 2.8M shares of Ginkgo Bioworks on Monday 07:38 DNA
Show links to two entry/exits that were definitive. It's like LESL, if it was $35 you'd be crowing about a perfect call. Saying SNAP has topped at $78 doesn't count. I could be wrong, but I sure don't remember 5 open/close trades Stoney.
Intrusion announces Lippert accelerates its INTRUSION Shield deployment 09:02 INTZ Zymeworks, ALX Oncology dose 1st patient in Zanidatamab-ALX148 trial for cancer 08:37 ZYME, ALXO Zymeworks Inc. (ZYME), and ALX Oncology (ALXO) announced the first patient has been dosed in an open-label, multi-center Phase 1b/2 clinical trial conducted by Zymeworks. The trial is designed to evaluate the safety and efficacy of zanidatamab, Zymeworks' lead HER2-targeted bispecific antibody, in combination with evorpacept , ALX's CD47 blocker, in patients with advanced HER2-positive breast cancer, HER2-low breast cancer and additional non-breast HER2-expressing solid tumors. This collaboration builds on the promising antitumor activity observed in clinical trials of evorpacept combined with a HER2-targeted antibody in patients with advanced HER2-positive gastric or gastroesophageal junction cancer. The addition of CD47 blockade is designed to enhance zanidatamab's immunotherapeutic effects and has the potential to provide benefit to a broad population of patients, including those with advanced HER2-expressing breast cancer and potentially other HER2-expressing cancers.
Van it may be seven! I don't have the time to go get you every one but here's another! each time the stk has been around $71 it has worked out-